Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Sci Rep ; 7(1): 15480, 2017 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-29133816

RESUMEN

We have devised an effective and robust method for the characterization of gene-editing events. The efficacy of editing-mediated mono- and bi-allelic gene inactivation and integration events is quantified based on colony counts. The combination of diphtheria toxin (DT) and puromycin (PM) selection enables analyses of 10,000-100,000 individual cells, assessing hundreds of clones with inactivated genes per experiment. Mono- and bi-allelic gene inactivation is differentiated by DT resistance, which occurs only upon bi-allelic inactivation. PM resistance indicates integration. The robustness and generalizability of the method were demonstrated by quantifying the frequency of gene inactivation and cassette integration under different editing approaches: CRISPR/Cas9-mediated complete inactivation was ~30-50-fold more frequent than cassette integration. Mono-allelic inactivation without integration occurred >100-fold more frequently than integration. Assessment of gRNA length confirmed 20mers to be most effective length for inactivation, while 16-18mers provided the highest overall integration efficacy. The overall efficacy was ~2-fold higher for CRISPR/Cas9 than for zinc-finger nuclease and was significantly increased upon modulation of non-homologous end joining or homology-directed repair. The frequencies and ratios of editing events were similar for two different DPH genes (independent of the target sequence or chromosomal location), which indicates that the optimization parameters identified with this method can be generalized.


Asunto(s)
Sistemas CRISPR-Cas/genética , Edición Génica/métodos , Antígenos de Histocompatibilidad Menor/genética , Proteínas/genética , Proteínas Supresoras de Tumor/genética , Alelos , Toxina Diftérica/administración & dosificación , Técnicas de Inactivación de Genes/métodos , Vectores Genéticos/genética , Histidina/análogos & derivados , Histidina/biosíntesis , Humanos , Células MCF-7 , Antígenos de Histocompatibilidad Menor/metabolismo , Proteínas/metabolismo , Puromicina/administración & dosificación , Transfección/métodos , Transgenes/genética , Proteínas Supresoras de Tumor/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA